Crescita Therapeutics Inc. (CTX.TO)
CAD 0.57
(1.79%)
CAD 0.57
(1.79%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.95 Million CAD | -367.21% |
| 2022 | 732 Thousand CAD | 238.37% |
| 2021 | -529 Thousand CAD | -121.04% |
| 2020 | 2.51 Million CAD | -36.68% |
| 2019 | 3.97 Million CAD | 10829.73% |
| 2018 | -37 Thousand CAD | 99.44% |
| 2017 | -6.57 Million CAD | 54.9% |
| 2016 | -14.56 Million CAD | 5.16% |
| 2015 | -15.36 Million CAD | -13.98% |
| 2014 | -13.47 Million CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.04 Million CAD | -42.82% |
| 2024 Q1 | -731 Thousand CAD | -546.9% |
| 2023 Q4 | -113 Thousand CAD | 91.82% |
| 2023 FY | -1.95 Million CAD | -367.21% |
| 2023 Q3 | -1.38 Million CAD | -511.06% |
| 2023 Q2 | -226 Thousand CAD | -271.21% |
| 2023 Q1 | 132 Thousand CAD | -76.92% |
| 2022 Q1 | -342 Thousand CAD | -130.67% |
| 2022 FY | 732 Thousand CAD | 238.37% |
| 2022 Q4 | 572 Thousand CAD | 168.54% |
| 2022 Q3 | 213 Thousand CAD | 6.5% |
| 2022 Q2 | 200 Thousand CAD | 158.48% |
| 2021 FY | -529 Thousand CAD | -121.04% |
| 2021 Q3 | -860 Thousand CAD | -27.03% |
| 2021 Q4 | 1.11 Million CAD | 229.65% |
| 2021 Q1 | -297 Thousand CAD | 59.2% |
| 2021 Q2 | -677 Thousand CAD | -127.95% |
| 2020 Q4 | -728 Thousand CAD | -118.81% |
| 2020 Q2 | -1.22 Million CAD | -239.61% |
| 2020 FY | 2.51 Million CAD | -36.68% |
| 2020 Q1 | -361 Thousand CAD | 38.4% |
| 2020 Q3 | 3.87 Million CAD | 415.66% |
| 2019 Q3 | 478 Thousand CAD | -89.63% |
| 2019 Q4 | -586 Thousand CAD | -222.59% |
| 2019 FY | 3.97 Million CAD | 10829.73% |
| 2019 Q1 | 467 Thousand CAD | -65.46% |
| 2019 Q2 | 4.6 Million CAD | 886.94% |
| 2018 Q3 | 508 Thousand CAD | 131.44% |
| 2018 Q4 | 1.35 Million CAD | 166.14% |
| 2018 Q1 | -281 Thousand CAD | 92.18% |
| 2018 FY | -37 Thousand CAD | 99.44% |
| 2018 Q2 | -1.61 Million CAD | -475.09% |
| 2017 Q1 | -3.09 Million CAD | 35.72% |
| 2017 Q4 | -3.59 Million CAD | -739.49% |
| 2017 FY | -6.57 Million CAD | 54.9% |
| 2017 Q3 | -428 Thousand CAD | -179.11% |
| 2017 Q2 | 541 Thousand CAD | 117.5% |
| 2016 Q2 | -3.04 Million CAD | 46.36% |
| 2016 FY | -14.56 Million CAD | 5.16% |
| 2016 Q4 | -4.8 Million CAD | -66.69% |
| 2016 Q1 | -5.66 Million CAD | 45.43% |
| 2016 Q3 | -2.88 Million CAD | 5.1% |
| 2015 Q4 | -10.38 Million CAD | -364.19% |
| 2015 Q2 | -5.44 Million CAD | -141.21% |
| 2015 Q3 | -2.23 Million CAD | 58.95% |
| 2015 FY | -15.36 Million CAD | -13.98% |
| 2015 Q1 | -2.25 Million CAD | 0.0% |
| 2014 FY | -13.47 Million CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aurora Cannabis Inc. | -46.45 Million CAD | 95.789% |
| Avicanna Inc. | -7.93 Million CAD | 75.344% |
| Avant Brands Inc. | -1.45 Million CAD | -34.804% |
| Cardiol Therapeutics Inc. | -29.78 Million CAD | 93.433% |
| Knight Therapeutics Inc. | -2.89 Million CAD | 32.318% |
| MediPharm Labs Corp. | -18.25 Million CAD | 89.283% |
| OrganiGram Holdings Inc. | -242.73 Million CAD | 99.194% |
| Canopy Growth Corporation | -228.71 Million CAD | 99.145% |
| Willow Biosciences Inc. | -13.18 Million CAD | 85.162% |
| Auxly Cannabis Group Inc. | -19 Million CAD | 89.708% |